Multiple squamous cell carcinomas following introduction of nilotinib
P Peters1, D Rabbolini, S Sinnya
1Queensland Institute of Dermatology, Brisbane, QLD, Australia; School of Medicine, University of Queensland, Brisbane, QLD, Australia.
Background:
Nilotinib is a second generation tyrosine kinase inhibitor, used in the treatment of chronic myelogenous leukaemia (CML).
Methods:
We assessed a 72-year-old woman who was treated with nilotinib for CML.
Results:
During the year following commencement of nilotinib, the patient developed eight squamous cell carcinomas (SCCs) on her legs.
Conclusions:
Development of SCC is a previously unreported adverse reaction to nilotinib.
More Related Videos
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Targeted Cancer Therapies
There are several types of targeted therapies against...
